Floatz logo

Prevnar 20

Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)vaccinePhase 4 / ApprovedActive
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

287 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
Vinblastine
Intensity Therapeutics, Inc.
Phase 4BBB
Prednisolone
The Lymphoma Academic Research Organisation
Phase 4BBB
Cyclophosphamide
Beth Israel Deaconess Medical Center
Phase 4BB
Vincristine Sulfate
Inhye Ahn
Phase 3BB
Bleomycin
Shandong Provincial Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Prevnar 20 is also rated in:

pneumococcal infectionActive
BB
Indicative · Phase 4
65 / 100
View asset →
non-Hodgkin lymphomaActive
B
Indicative · Phase 4
59 / 100
View asset →
sickle cell diseaseActive
CCC
Indicative · Phase 3
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →